CD13, Mouse, mAb ER-BMDM1
The monoclonal antibody ER-BMDM1 is directed against a 160-kDa cell membrane-associated antigen with aminopeptidase N activity. Aminopeptidase N (APN) is also known as Alanyl Aminopeptidase (ANPEP), CD13 antigen or membrane protein p161. The protein consists of a short cyplasmic tail, a transmembrane region, a Ser/Thr region, and a zinc metalloproteinase domain. Widely expressed in many cells, tissues, and species, aminopeptidase N cleaves the N-terminal amino acids from bioactive peptides, leading to their inactivation or degradation. It has putative involvement in several biological processes including antigen processing and presentation, cell adhesion, tumor invasion and metastasis and neurotransmitter degradation. The antigen recognized by the monoclonal antibody ER-BMDM1 is present on various mouse macrophage and dendritic cell subpopulations as well as on microvillous epithelia. The ER-BMDM1 antigen is expressed at increasing levels upon maturation of macrophages. Therefore the monoclonal antibody ER-BMDM1 is a useful marker for the identification of aminopeptidase N positive macrophages and dendritic cells in mouse, the expression of the ER-BMDM1 antigen arises after the monocytic stage of differentation: bone marrow cells and peripheral blood monocytes are ER-BMDM1 negative, whereas mature macrophages express the ER-BMDM1 antigen. A subpopulation of dendrocytes and their in vitro equivalents, the dendritic cells, are also ER-BMDM1 positive.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA